Impact of between-tissue differences on pan-cancer predictions of drug sensitivity
Open Access
- 25 February 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 17 (2) , e1008720
Abstract
Increased availability of drug response and genomics data for many tumor cell lines has accelerated the development of pan-cancer prediction models of drug response. However, it is unclear how much between-tissue differences in drug response and molecular characteristics may contribute to pan-cancer predictions. Also unknown is whether the performance of pan-cancer models could vary by cancer type. Here, we built a series of pan-cancer models using two datasets containing 346 and 504 cell lines, each with MEK inhibitor (MEKi) response and mRNA expression, point mutation, and copy number variation data, and found that, while the tissue-level drug responses are accurately predicted (between-tissue ρ = 0.88–0.98), only 5 of 10 cancer types showed successful within-tissue prediction performance (within-tissue ρ = 0.11–0.64). Between-tissue differences make substantial contributions to the performance of pan-cancer MEKi response predictions, as exclusion of between-tissue signals leads to a decrease in Spearman’s ρ from a range of 0.43–0.62 to 0.30–0.51. In practice, joint analysis of multiple cancer types usually has a larger sample size, hence greater power, than for one cancer type; and we observe that higher accuracy of pan-cancer prediction of MEKi response is almost entirely due to the sample size advantage. Success of pan-cancer prediction reveals how drug response in different cancers may invoke shared regulatory mechanisms despite tissue-specific routes of oncogenesis, yet predictions in different cancer types require flexible incorporation of between-cancer and within-cancer signals. As most datasets in genome sciences contain multiple levels of heterogeneity, careful parsing of group characteristics and within-group, individual variation is essential when making robust inference.Keywords
All Related Versions
Funding Information
- Michigan Institute for Clinical and Health Research – Postdoctoral Translational Scholar Program (UL1TR002240)
- Breast Cancer Research Foundation
- Michigan Institute for Data Science
- National Institutes of Health (1R21CA218498-01)
- National Institutes of Health (R01GM118928-01)
This publication has 46 references indexed in Scilit:
- Precision Oncology: An OverviewJournal of Clinical Oncology, 2013
- Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical PropertiesPLOS ONE, 2013
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Research, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancersGenome Biology, 2011
- Differential expression analysis for sequence count dataGenome Biology, 2010
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)Cancer Research, 2010
- PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer dataBiostatistics, 2009
- Invited review: Genomic selection in dairy cattle: Progress and challengesJournal of Dairy Science, 2009